Picture of Eli Lilly and Co logo

LLY — Eli Lilly and Co Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Momentum

Relative Strength (%)
1m+12.96%
3m+39.19%
6m+37.96%
1yr+62.52%
Volume Change (%)
10d/3m+2.03%
Price vs... (%)
52w High-2.23%
50d MA+4.65%
200d MA+17.22%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)34.95
PEG Ratio (f)3.95
EPS Growth (f)9.7%
Dividend Yield (f)1.31%
Valuation (ttm)IndustryMarket
Price to Book Value31.26
Price to Tang. Bookn/a
Price to Free Cashflow50.09
Price to Sales9.95
EV to EBITDA34.61

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital21.47%
Return on Equity75.53%
Operating Margin24.56%

Financial Summary

Year End 31st DecUnit201720182019202020212022E2023ECAGR / Avg
Total Revenue$m19,973.821,493.322,319.524,539.828,318.429,063.7130,236.035.94%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+112.22-12.7+6.15+33.92+2.16+6.67+13.97n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for LLY

Four signs of a competitive moat at Eli Lilly And Co (NYQ:LLY) background image

Four signs of a competitive moat at Eli Lilly And Co (NYQ:LLY)

Given that widespread uncertainty in the stock market is likely to endure for the rest of 2020 and beyond, it pays to know that you're investing in high-quality stocks, rather than speculative ones. This means safe, profitable companie...

Why having a high ROE helps shareholders of Eli Lilly And Co background image

Why having a high ROE helps shareholders of Eli Lilly And Co

Return on equity (ROE) measures how efficiently a company uses Shareholders’ Equity to generate profits. For any readers unfamiliar with ROE, it is calculated by dividing net income by book value of equity. It’s no coincidence that War...

What's the future for the Eli Lilly And Co (NYQ:LLY) share price? background image

What's the future for the Eli Lilly And Co (NYQ:LLY) share price?

Given the present disruption and volatility in the stock market, it is more important than ever to identify high quality stocks for your portfolio. That means knowing how to find highly profitable companies that are able to fend off co...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Eli Lilly and Co EPS forecast chart

Profile Summary

Eli Lilly and Company is a drug manufacturing company. The Company is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The Company's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The Company's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
January 17th, 1901
Public Since
July 9th, 1970
No. of Shareholders
20,641
No. of Employees
35,000
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNew York Stock Exchange
Shares in Issue
950,159,559

LLY Share Price Performance

Latest News for LLY

Upcoming Events for LLY

Eli Lilly and Co Diabetes & Obesity Update at ADA Call

Q2 2022 Eli Lilly and Co Earnings Release

Q2 2022 Eli Lilly and Co Earnings Call

Q3 2022 Eli Lilly and Co Earnings Release

Q3 2022 Eli Lilly and Co Earnings Call

Similar to LLY

Picture of Abbvie logo

Abbvie

us flag iconNew York Stock Exchange

Picture of Amneal Pharmaceuticals logo

Amneal Pharmaceuticals

us flag iconNew York Stock Exchange

Picture of Bausch Health Companies logo

Bausch Health Companies

us flag iconNew York Stock Exchange

Picture of Bristol-Myers Squibb Co logo

Bristol-Myers Squibb Co

us flag iconNew York Stock Exchange

Picture of Bristol-Myers Squibb Co logo

Bristol-Myers Squibb Co

us flag iconNew York Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email